Is Your Oncology Practice Ready for CMS-0057-F in 2027? How to Streamline Prior Authorization and Improve Revenue Cycle Efficiency
Prepare for CMS-0057-F with smarter oncology prior authorization workflows. Explore 2027 requirements, reduce approval delays, and improve revenue cycle.
Timely cancer treatment in oncologic practices is a tricky proposition with intricate insurance needs. Delays in committing to treatments to a facility can interfere with treatment plans, increase administration costs and delay reimbursement. While the CMS interoperability guidelines will be introduced for the 2027 mandate, practices need to get ready for the changes to their systems and process in advance.
During the study period, 74% of adults with cancer (1,201 people) said they were required to obtain prior authorization. Patients/family members directly responsible for the authorization process said that they took several days, typically business days, to deal with one authorization. The findings show the importance of patient access as it applies to oncology prior authorization as well as the revenue cycle management priority.
Delayed claims aren’t the only consequences for practice leaders. Staff’s time spent gathering records, correcting submissions, following up with payers and trying to appeal denials takes away staff time from operations. Planning for oncology advance certification can enable practices to better document, hold practices obtainable, and minimize avoidable, delayed reimbursement.
What Does CMS-0057-F Mean for Oncology Practices?
The Centers for Medicare & Medicaid Services (CMS)’s 2024 Interoperability and Prior Authorization Final Rule is CMS-0057-F. It sets requirements for some affected health plans to make it easier to exchange electronic information and prior authorized medical services. A number of API related requirements take effect in 2027; for some it is as early as 2026 for operational requirements.
The purpose of the rule is to have more information about authorization readily available and eliminate reliance on de-coupled administrative processes. These changes will need to be considered by Oncology prior authorization teams when evaluating their workflow. Better access to payer requirements and a more uniform denial process and more uniform e-workflows where supported are some of the implications for oncology practices.
Key CMS-0057-F Requirements and Timeline
| Requirement | What It Means | General Compliance Timeline |
|---|---|---|
| Prior Authorization API | Supports electronic requests, documentation requirements, and responses | Beginning in 2027 |
| Provider Access API | Allows participating payers to share specified patient information with eligible in-network providers | Beginning in 2027 |
| Patient Access API updates | Adds specified prior authorization information for patient access | January 1, 2027 |
| Payer-to-Payer API | Supports specified data exchange between payers, subject to applicable requirements | Beginning in 2027 |
| Faster authorization decisions | Establishes maximum response timeframes for covered non-drug requests under applicable programs | Beginning in 2026 |
| Specific denial reasons | Requires more specific explanations for covered authorization denials | Beginning in 2026 |
Actual dates are subject to the type of payer and program eligible. Practices should understand the rules of each specific plan more thoroughly, and not assume that each of the commercial plans will have the same rules.
How the Rule Affects Oncology Revenue Cycle Operations
Medical necessity reviews and approval of cancer treatment will not be eliminated with CMS-0057-F and will not guarantee approval. It will provide information exchange and administrative processes with regards to covered items/services. Individual payer policies, documentation and authorization requirements must still be met for practices. CMS-0057-F should thus form part of a wider, oncology prior authorization improvement program.
Oncology prior authorization preparation for revenue cycle teams should involve checking all services that will need approval and the various ways the payers accept requests for prior authorization. It should also ensure the staff members are aware of the process for determining whether a patient is authorized by the practice before treating them and reconciling that authorization with claims.
Why Oncology Prior Authorization Creates Financial Pressure
Your care for your cancer may be complex, require time-sensitive treatment, require extensive clinical documentation and may be costly. Rounding errors, lack of staging data or treatment information can delay decision making. The practice could need to reschedule the time the infusion is administered and repeat the administration process if the problem is discovered by staff very close to the scheduled time for the infusion.
Previously, ASCO surveyed oncology professionals on these issues with 97 percent saying that the burden of documentation requirements exists and 97 percent saying insurers take a long time to respond. The results are based on the quoted administrative challenges, and do not reflect the overall experiences of all the providers surveyed.
The financial implications are normally evident in one or more of the following ways:
- Late reimbursement: Claims might not be submitted, and/or may not be reviewed, due to corrections being made to the authorization of the claim.
- Preventable denials: Claim denials may be preventable as the claim may be denied if approval is missing, there is a lack of accurate service details or the authorization has expired.
- Increase in labor expenses: Workers put in extra hours collecting records, calling payers, and resubmitting corrected records.
- Treatment scheduling interruptions: Uncertainty regarding authorization can impact treatment appointments, imaging services, radiation treatment and treatment planning.
- Lack of clarity over financial performance: Poor tracking of payers, services and stages in the process of the financial performance are not easy to identify the delays.
Effective oncology prior authorization workflows can help practices detect such risks before they impact their treatment and finances. It can also enable leadership to detect any differences between delayed clinical review and problems along the internal process. This separation will provide a more valuable contribution for operational choices for oncology prior authorization reporting.
Which Oncology Services Commonly Require Authorization?
Authorizing requirements vary according to the services, place of service, health plan, benefit design and patient. Practices should not make the assumption that one payer’s policy is the same as the other. Verification should be done before a planned intervention service and in particular, for any changes that are made to the treatment plans. An Oncology prior authorization (PA) checklist can facilitate this control within the various departments.
| Service Category | Information to Verify | Common Workflow Risk |
|---|---|---|
| Chemotherapy and immunotherapy | Drug, regimen, diagnosis, dose, frequency, and applicable benefit | Drug or regimen details do not match the approval |
| Specialty medications | Coverage pathway, pharmacy requirements, and medical necessity | Request submitted through the wrong benefit channel |
| Radiation therapy | Treatment plan, approved services, and authorized treatment course | Authorization does not cover the complete planned course |
| Diagnostic imaging | Modality, clinical indication, and ordering provider | Missing clinical notes or incorrect service details |
| Molecular and genetic testing | Test indication, applicable policy, and supporting clinical documentation | Insufficient documentation for payer review |
| Outpatient procedures | Procedure details, site of care, and network requirements | Authorization does not match the billed service |
This is an operational example table, it isn’t a list of authorizations. Current-payer policies should be utilized by oncology prior authorization teams to identify processes that need authorization and documentation required for these processes.
Individual drug authorization requirements shall also be subject to individual review. It is not advisable to see medical-benefit oncology prior authorization and pharmacy-benefit requests as one and the same. CMS issued the proposed CMS-0062-P rule in April 2026, to incorporate the requirements for electronic authorizations to certain medications. Since this is a proposed rule, practices should make sure to differentiate between procedures which are proposed versus procedures which are final and follow-up any procedural guidance provided by CMS.
How to Build a More Reliable Authorization Workflow
Scheduling, clinical documentation, authorization, coding and billing are tightly interwoven in a reliable process. Team conflicts can lead to non-received approvals or submit claims that are not in line with the approved treatment. By having a standardized workflow, you will have a definite owner and status for each request. This is a stepping stone toward a more consistent oncology prior authorization process.
1. Verify Requirements Before Scheduling
Start with determining the eligibility, benefits, network membership, and authorization criteria. Determine if the proposed service will be considered medical or pharmacy benefit. Document the intended means of submission, clinical information that is needed and any deadlines. This early verification can signal issues before the day of treatment hits the oncology prior authorization team and make it one tougher to shift coverage. Requirements should also be rechecked by staff when a change to a regimen, or dose, treatment location or service occurs. These changes may trigger new oncology prior authorization actions per individual carriers’ policies.
2. Standardize Clinical Documentation
Establish documentation checklists of typical categories of treatment and/or healthcare plans for payers. Supporting records can vary by service and range from a diagnosis to the pathology to the staging, prior treatments, imaging, etc., and the proposal of treatment. This checklist should be tailored to align with the existing payment policy and should not be a list of documents. It is the staff’s responsibility to verify clinical information submitted fulfills the need for requested services and matches the order. Once the records are complete, this can help minimize unnecessary oncology prior authorization follow-up.
3. Track Every Request in a Central Queue
A centralized queue makes it easy for staff to keep track of pending, approved and denied requests and also incomplete. The date of filing the record, the payer, the service, date of treatment, and the owner, a reference number, and the next actions should be included on each record. Utilize escalation procedures for emergency cases and coming up with appointments for treatment. An established follow up system decreases reliance on individual Inboxes and allows an individual’s outstanding requests to be seen by bosses. It also enables to track oncology prior authorization activity in more detail, providing an effective audit trail.
4. Confirm Approval Details Before Treatment
Approval by an authorization number does not mean that it covers all planned services. Staff to review the approved drug/please use procedure (if there is one), units or visits (if applicable), provider, location, effective dates and any conditions stated on the drug. This is a critical point of oncology prior authorization due to patients’ treatment plans changing throughout treatment. The approved details must always reflect the order; staff must find out the discrepancy between the order and the approved details prior to billing and, when medically appropriate, the provision of the service. This last verification is important for minimizing oncology prior authorization mismatches to claims.
5. Reconcile Authorization Records With Claims
When filing a claim, you should verify the billed service with authorization records. Verify that if applicable, the claim has the appropriate: code, date of service, unit, rendering provider, and location. If a denial is received, clarify if missing authorization, documentation, expired authorization, coding mismatch or payer processing problem was the cause. Give the corrections to the right teams and monitor the results. Having a typology of the root cause helps guide targeted changes to the oncology prior authorization process.
Preparing Your Practice for the 2027 CMS Requirements
To make 2027 readiness a workflow and technology project, rather than merely an IT policy upgrade. CMS API requirements are applicable to certain payers, although when providers are adopting and leveraging supported electronic workflows can impact their readiness to operate. Oncology practices should ensure that their responsibilities and incentives are determined by their EHR vendors and clearinghouses and participating payers. This review should help to resolve where oncology prior authorization automation is available and where there is need for manual follow-up.
Audit Current Authorization Performance
Check back over the last 3-6 months of authorizations. Highlight high volume payers, often delayed services, incomplete submission, recurring denials and treatment appointments impacted as the result of non-final approvals. The audit should create a standard for the performance of oncology prior authorizations. If there is no baseline data available, leaders can’t evaluate if process changes are working to increase ability to deliver on turnaround time, to decrease rework, or to ensure reimbursement.
Review EHR and Technology Capabilities
Inquire from EHR and technology vendors about the existing electronic authorization methods, and those that rely on the implementation of the payers. Decide if systems can share the necessary information, track requests, keep necessary records, and deliver reportable information. Remember that although API reduces manual processes, that alone doesn’t mean it completely replaces them. For un-supported payers, forms that can’t be answered electronically, emergencies and clinical information or missing needed to answer, procedures must still be worked out by staff.
Assign Clear Ownership
Explain the accountability for scheduling, clinical personnel, authorization, coding and billing. Determine: who is responsible for checking coverage, who is responsible for making the request, who follows up and who makes the confirmation that the approval is accurate to the planned service. It’s also important that ownership contains a clear pathway when treatment is nearing the end of the authorizing process when it is still not approved (for oncology). Managers must be able to see outstanding cases, but not just get casual updates on them. oncology prior authorization ensures ongoing progress of the oncology authorizations in line with the treatment service agreements and escalation rules.
Create Payer-Specific Procedures
Have a reference guide of each of the big payers. Indicate how to submit, what is needed to submit, when they need to be renewed, any contacts to follow-up, and what to do if needed. Update the guide if there are any policy changes by a payer or practice workflow changes. These procedures must be able to differentiate CMS Finalized rules from payer specific rules and proposed rules and regulations. Compliance distinctions come through to prevent compliance presumptions from turning into costly billing mistakes. It also helps to make oncology prior authorization processes up-to-date and reflects the shifts in payer policies.
Metrics That Reveal Authorization and Revenue Cycle Problems
Operational metrics allow leaders access to useful data points to gauge whether there are measurable financial benefits to authorization improvements. Compare performance: by Payer, Service Type, Location, responsible team. A single average for the practice as a whole may mask some bad issues with high-cost treatments.
| Metric | What It Measures | Why It Matters |
|---|---|---|
| Authorization turnaround time | Time from submission to decision | Reveals delays affecting scheduled services |
| First-pass completeness | Requests accepted without missing information | Identifies documentation quality problems |
| Authorization-related denial rate | Claims denied for authorization issues | Connects workflow failures to reimbursement risk |
| Approval-to-claim match rate | Claims consistent with authorization details | Highlights mismatches before or after submission |
| Pending authorization aging | Time requests remain unresolved | Helps teams prioritize overdue and high-risk cases |
| Rework hours | Staff time spent correcting or resubmitting requests | Quantifies avoidable administrative effort |
| Dollars delayed or denied | Financial value of affected claims | Helps leadership prioritize improvement projects |
Apply uniform definitions and reporting periods to enable results to be compared over time. While this is helpful, it also needs to be measured in the context of access to treatment in a timely manner, the quality of treatment being approved, and the commitment of the total staff. All these measures indicate if oncology prior authorization control is improving performance. Work out the administrative rework costs.
Calculate the Cost of Administrative Rework
So, let’s imagine that the only thing you have to do is to follow up on things that are preventable with 80 staff hours a month, and that means a lot more work than that. This works out at a supposed $30.00 per hour, so the monthly income would be $2400.00 and the yearly income $28,800.00. This is a sample calculation and will not be an industry standard or a guaranteed savings figure. Own field practices should calculate values for the labor opportunity based on their own labor rate and rework labor counted hours. Improvements in Oncology prior authorizations can then be measured and compared to “baseline” to demonstrate measurable operational value.
How Revenue Cycle Support Can Improve Authorization Management
In certain circumstances, Oncology practices may need extra assistance in addressing the increase in request volumes, the lack of documentation, communication with payers and authorizations or denials. Revenue cycle support can be beneficial in coordinating these activities and linking the authorization status to the billings result.
Billing Care Solutions is a leading provider of revenue cycle management solutions for healthcare companies in the Oncology segment. Handling various Billing and Business Services needs such as Claim Submission, Claims Denial Management, Payment Posting, Coding Audits and Financial Reporting. Appointment scheduling, claim tracking, and claim reconciliation (if within the scope of agreement) are examples of areas of the oncology revenue cycle that requires assistance for a practice; these are identified when workflow is analyzed.
It’s about making it visible for it to work, not just about transferring something to another team. Practices should have measurable expectations for turnaround time; request cases that are not yet completed; not enough cases going to denial; who’s reporting cases; and how often cases are reported. These tools assist leaders to check for external support’s impact on their workflow performance and financial control. A focused review can be useful to identify how important oncology prior authorization can be to improve measurably.
Final Thoughts on Oncology Prior Authorization Readiness
The 2027 CMS interoperability requirements represent a timely opportunity to explore authorization processes, payer communication and technology preparedness. But requirements and deadlines differ among payers and the final rule doesn’t eliminate all authorization requirements. Practices need to verify rules that apply and plan processes on real-life policies from payers.
The first steps in a practical readiness plan include workflow audits, standardizing the documentation, tracking centrally and defining ownership. It additionally links authorization data to treatment plans as well as claim outcomes. Oncology leaders can understand the areas for improvement through measuring turnaround time, the amount of rework, denial rate and delayed reimbursement to have the most operational and financial impact. The key is to improve oncology prior authorization, to make it more predictable, traceable, and affordable, without compromising access to medically necessary cancer services.
